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We report a new use of dendrimer-entrapped gold nanoparticles (Au DENPs) modified by polyethylene glycol (PEG)
with good biocompatibility for in vitro and in vivo imaging of atherosclerotic mice by computed tomography (CT).
In this study, Au DENPs were synthesized using poly(amidoamine) (PAMAM) dendrimers of generation 5 (G5.NH2)
modified by PEG monomethyl ether (G5.NH2-mPEG20) as templates. In vitro cytotoxicity and flow cytometry assays
show that the formed PEGylated Au DENPs have good biocompatibility and are non-cytotoxic at the Au concentration
up to 300 μM. Silver staining and transmission electron microscopy (TEM) further confirm that the Au DENPs are able to
be uptaken by macrophages and are located dominantly in the lysosomes of the cells. Importantly, the formed
PEGylated Au DENPs are able to be used for CT imaging of murine macrophages in vitro and macrophages in
atherosclerotic mice in vivo using apolipoprotein-E-gene-deficient mice as a model. These findings suggest that the
formed PEGylated Au DENPs are a promising contrast agent for CT imaging of atherosclerosis.
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Atherosclerosis and its complications are the leading
causes of morbidity and mortality in modern societies
[1,2]. Atherosclerosis is a processed disease, characterized
by endothelial injury, lipid deposition, inflammation, and
plaque formation [3-6]. Among the complications, rup-
tures of vulnerable atherosclerotic plaques are the major
cause of death in cardiovascular diseases [7,8]. Thus, the
enhancement of early detection and identification of pa-
tients who are prone to plaque rupture is highly import-
ant. Recent studies have emerged to show the importance
of macrophages in the formation and progression of ath-
erosclerosis [9,10], and the high macrophage content is* Correspondence: pengchen_1985@163.com; jiangme2013@163.com;
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in any medium, provided the original work is pone of the principal factors associated with plaque instabil-
ity [11]. Thus, new platforms and technologies are crucial
for noninvasive imaging and assessment of the macro-
phage burden in atherosclerotic plaques.
The emergence of molecular imaging (MI) has drastic-
ally changed medical science in many ways, including the
diagnosis of diseases in the early stages, the assessment of
risks, the treatment outcome, and the follow-up [12-14].
Computed tomography (CT), one of the most reliable MI
modalities, is widely used in cardiovascular diseases be-
cause of its properties of high resolution, sharp contrast,
three-dimensional (3D) capabilities, and low cost in com-
parison to other imaging modalities [15-17]. Numerous
studies showed that the key element in CT imaging of
cardiovascular diseases is to design applicable and safe
contrast agents with long imaging time, sharp contrast
sensitivity, and excellent stability in vitro and in vivo
[18,19]. Given that clinically used ionic or non-ionic CT
contrast agents have several drawbacks such as allergic
reaction, short imaging time, renal toxicity at high con-
centrations, and nonspecificity [20,21], developing novel
nanoparticle (NP)-based contrast agents with excellentpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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crucial for CT imaging.
Gold nanoparticles (AuNPs), one of the most promising
nanomaterials, are widely used as X-ray CT imaging con-
trast agents in the diagnosis and therapy of tumors be-
cause of their in vitro and in vivo stability, easy surface
modification, good biocompatibility, and higher X-ray at-
tenuation characteristics than those of clinically used ionic
or non-ionic iodinated CT contrast agents [17,22]. How-
ever, to develop AuNP-based CT contrast agents with de-
sirable properties, such as good biocompatibility, easy and
controllable surface modification, sharp contrast, and pro-
longed imaging time [23-25], multiple complicated steps
are generally required. Recent studies have shown that
proper modification of AuNPs can extend their circulation
time in cardiovascular diseases by decreasing the rapid up-
take and clearance by the reticuloendothelial system (RES)
[19,26-28]. One promising and efficient technique to
achieve this goal is to modify AuNPs with polyethylene
glycol (PEG) molecules [29,30].
In our previous reports [31,32], we have shown that acet-
ylated dendrimer-entrapped AuNPs (Au DENPs) synthe-
sized using generation 5 (G5) poly(amidoamine) (PAMAM)
dendrimers as templates are able to be used as contrast
agents for CT imaging of C57 mice after intravenous in-
jection. X-ray absorption coefficient measurements verified
that the X-ray attenuation of Au DENPs was significantly
higher than that of clinically used iodinated contrast agents
at the same concentration (Au versus iodine) [32,33]. The
inferior vena cava (IVC) and pulmonary veins of the mice
were clearly identified after intravenous injection of the Au
DENPs. In our another work [29], we have shown that Au
DENPs formed using PEGylated G5 dendrimers as tem-
plates have improved biocompatibility and are able to be
used as contrast agents for blood pool and tumor CT im-
aging. These prior successes lead us to hypothesize that
PEGylated Au DENPs can also be used to image blood pool
in atherosclerotic mice in vitro and in vivo.
In this study, PEGylated Au DENPs were generated
using G5 PAMAM dendrimers modified with PEG as
templates. The formed PEGylated Au DENPs were sys-
tematically assessed in terms of their stability, biocompati-
bility, X-ray attenuation characteristics, and feasibility as
contrast agents for CT imaging of murine macrophages in
atherosclerosis. The biocompatibility of PEGylated Au
DENPs was evaluated by cell counting kit-8 (CCK-8) assay
for cell viability and flow cytometry for cell apoptosis. The
distribution of Au DENPs within macrophages associated
with atherosclerosis was observed by silver staining and
transmission electron microscopy (TEM). Then, the
PEGylated Au DENPs were used to diagnose the athero-
sclerotic mice model successfully. To our knowledge,
this is the first report related to the PEGylated Au
DENPs used as contrast agents for CT imaging of bloodpool in atherosclerotic mice in vitro and atherosclerotic
mice model in vivo.
Methods
Materials
Ethylenediamine core amine-terminated G5 dendrimers
(G5.NH2) with a polydispersity index less than 1.08 were
purchased from Dendritech (Dendritech Inc., Midland,
MI, USA). PEG monomethyl ether with one end of malei-
mide (mPEG-MAL) was from Shanghai Yanyi Biotechnol-
ogy Corporation (Shanghai, China). All other chemicals
were obtained from Aldrich (Sigma-Aldrich, St. Louis,
MO, USA) and used as received. Ana-1 cell line (a mouse
macrophage cell line) was purchased from Shanghai Cell
Bank, the Chinese Academy of Sciences (Shanghai, China).
Penicillin, streptomycin, and fetal bovine serum (FBS)
were purchased from Sigma (Sigma-Aldrich, St. Louis,
MO, USA). Trypsin-EDTA, Dulbecco's PBS, RPMI 1640
medium, and bovine serum albumin were obtained from
GIBCO-BRL (Life Technologies, Gaithersburg, MD, USA).
The water used in all the experiments was purified using a
Milli-Q Plus 185 water purification system (Millipore,
Bedford, MA, USA) with a resistivity higher than 18 mΩ
cm. Regenerated cellulose dialysis membranes (molecular
weight cutoff, MWCO= 10,000) were acquired from Fisher
(Thermo Fisher Scientific, Waltham, MA, USA).
Synthesis of [(Au0)300-G5.NHAc-mPEG] DENPs
The procedure used to synthesize [(Au0)300-G5.NHAc-
mPEG] DENPs was adopted from our previous report
[29]. The solution of G5.NH2-mPEG and HAuCl4 (molar
ratio between G5.NH2-mPEG and HAuCl4 is 1 to 300)
was mixed for 30 min, followed by an addition of NaBH4
(four times molar excess of the Au salt) solution (V
(H2O):V(CH3OH) = 1:1) under vigorous stirring for 2 h
to obtain a wine red solution (denoted as [(Au0)300-G5.
NH2-mPEG] DENPs).
Then, triethylamine (five times molar excess of the total
primary amines of G5.NH2) was added to the aqueous so-
lution of [(Au0)300-G5.NH2-mPEG] DENPs while under
magnetic stirring. After 30 min, acetic anhydride (four
times molar excess of the total primary amines of G5.NH2)
was added to the above mixture solution under stirring,
and the mixture was allowed to react for 24 h. The final re-
action mixture solution was extensively dialyzed against
PBS buffer (three times, 4 L) and water (three times, 4 L)
for 3 days to remove the excess reactants and by-products,
followed by lyophilization to obtain the PEGylated Au
DENPs ([(Au0)300-G5.NHAc-mPEG] DENPs).
Characterization techniques
UV-vis spectra were obtained using a Lambda 25 UV/Vis
spectrophotometer (Perkin Elmer, Waltham, Massachusetts,
USA). Samples were dissolved in water before the
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analytical electron microscope (JEOL Ltd., Akishima-shi,
Japan) operating at 200 kV. An aqueous solution of
[(Au0)300-G5.NHAc-mPEG] DENPs (5 μL, 1 mg/mL)
was dropped onto a carbon-coated copper grid and air-
dried prior to measurements.
Cell culture and characterization
Murine macrophages Ana-1 cells were cultured in RPMI
1640 medium with 10% heat-inactivated FBS and 1% v/v
penicillin/streptomycin at 37°C and 5% CO2. Immuno-
fluorescent staining was performed to characterize the
Ana-1 cells. Ana-1 cells were fixed with 4% paraformalde-
hyde for 20 min at 37°C. After permeabilization in 0.3%
Triton-X100 (diluted in PBS), the cells were incubated with
10% goat serum albumin diluted in 0.5% bovine serum
albumin (BSA) for 30 min at 37°C to block nonspecific
antibody adhesion. The primary macrophage antibodies
F4/80 (rat monoclonal, 1:500 diluted in 0.5% BSA; Abcam,
Cambridge, UK) and MAC-3 (rat monoclonal, 1:500 di-
luted in 0.5% BSA; BD, Franklin Lakes, NJ, USA) were in-
cubated at 4°C overnight. After rinsing with PBS, Alexa
Fluor® 555 (goat anti-rat, 1:500 diluted in 0.5% BSA; Invi-
trogen, Grand Island, NY, USA) was applied and incubated
for 1 h at 37°C in the dark. After further washing with
PBS, the cell nuclei were counterstained with 4′,6-diami-
dino-2-phenylindole (DAPI) (1:500, diluted in 0.5% BSA,
DAKO, Real Carpinteria, CA, USA) for 20 s. After a final
washing with PBS, the cells were examined under fluores-
cence microscope (Nikon, Chiyoda-ku, Tokyo, Japan).
To characterize the phenotypes of Ana-1 cells, 1 × 106
cells were washed with PBS and incubated with phyco-
erythrin (PE)-conjugated anti-mouse antibodies against F4/
80 for 30 min at 4°C in the dark. Isotype control antibodies
were used as the control group (all from eBioscience, San
Diego, CA, USA). After washing, the cells were analyzed by
a flow cytometer (Beckman Coulter, Fullerton, CA, USA).
Cytotoxicity assay of PEGylated Au DENPs
The viability of macrophages treated with PEGylated Au
DENPs was evaluated via CCK-8 (Dojindo Laboratories,
Kumamoto, Japan) assay. The assays were carried out
according to the procedure described in a previous re-
port [34]. In brief, Ana-1 cells were seeded in 96-well
culture plates at a density of 1 × 105 cells per well in
quadruplicate and allowed to grow for 24 h. Then, the
medium was replaced by RPMI 1640 medium containing
PEGylated Au DENPs with different concentrations (0
to 4 μM), and the cells were incubated for 24 h at 37°C.
After treatment, the medium was aspirated and cells
were washed with PBS thrice. Then, 10 μL of CCK-8 di-
luted in 100 μL of fresh RPMI 1640 medium was added
to each well and the cells were incubated for additional
2 h at 37°C. The absorbance was measured at 450 nm.The assay was carried out according to the manufactur-
er's instructions. For each concentration of Au DENPs,
mean and standard deviation of the quadruplicate wells
were reported.
The cytotoxicity of PEGylated Au DENPs was further
examined by flow cytometric detection of cell apoptosis.
Ana-1 cells were seeded in 6-well plates at a density of 2 ×
106 cells per well in quadruplicate and grown to conflu-
ence for 24 h. The medium was replaced with a fresh
medium containing PEGylated Au DENPs with two differ-
ent concentrations (1 and 3 μM), and the cells were incu-
bated for 24 h. Then, the cells were harvested, washed
with PBS, fixed in 0.5% paraformaldehyde citrate buffer
for 2 h, centrifuged, and resuspended with PBS at a cell
density of 1 × 106 cells/mL. The cell suspensions were
stained with Annexin V for apoptosis tests and analyzed
by Cell Quest software (FACS Calibur, BD, Franklin Lakes,
NJ, USA).
In vitro micro-CT imaging of macrophages
Ana-1 cells were seeded in 6-well plates at a density of 2 ×
106 cells per well in triplicate and allowed to grow to 80%
to 90% confluence for 24 h. Then, Ana-1 cells were incu-
bated with fresh medium containing PEGylated Au DENPs
(0, 100, and 300 μM, respectively) for 4 h at 37°C. After
washing with PBS, cells were trypsinized, centrifuged, and
resuspended with 100 μL PBS in a 0.5 mL Eppendorf tube
containing approximately 4.0 × 106 Ana-1 cells for each
tube. The cell suspension in each tube was placed in a
self-designed scanning holder and then scanned using a
micro-CT imaging system (eXplore Locus, GE Healthcare,
London, Ontario, Canada) with the following operating
parameters: tube voltage, 80 kV; tube current, 450 μA; ex-
posure time, 400 ms; slice thickness, 45 μm; and scan field
of view, 45 × 80 mm. Images were reconstructed on a
micro-CT imaging workstation (GEHC microView, GE
Healthcare, London, Ontario, Canada) using the following
parameters: voxel, 45 × 45 × 45 μm; display field of view,
10 × 25 mm. CT values were acquired on the same work-
station using the software supplied by the manufacturer.
Each experiment was carried out in triplicate.
Cellular uptake of PEGylated Au DENPs
The cellular uptake of PEGylated Au DENPs was verified
by silver staining and TEM according to methods re-
ported in our previous work [17,29]. For silver staining
experiments, Ana-1 cells were seeded at a density of 2 ×
106 per well in 6-well plates inserted with polylysine-
coated cover slips for 24 h and treated with fresh
medium containing PEGylated Au DENPs (1 and 3 μM)
for 24 h at 37°C. After washing with PBS, the cells were
fixed in 4% paraformaldehyde solution for 2 h. Silver
staining was performed according to the manufacturer's
instruction. Cells were washed with PBS thrice, stained
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air-dried, dehydrated, cleaned, and mounted for light
microscope observation.
For TEM imaging of the cellular uptake of PEGylated
Au DENPs, Ana-1 cells were seeded at a density of 2 ×
106 per well in 6-well plates for 24 h to grow to 90%
confluence and treated with a fresh medium containing
PEGylated Au DENPs (3 μM) for 24 h at 37°C. After
washing thrice with PBS, the cells were trypsinized, cen-
trifuged, and fixed with 2.5% glutaraldehyde in 0.2 M
phosphate buffer (pH 7.2) for 12 h at 4°C, and post-fixed
with 1% OsO4 in 0.2 M phosphate buffer (pH 7.2) for
2 h at 4°C. After washing with the phosphate buffer,
the cells were dehydrated in a series of ethanol so-
lutions of 30%, 50%, 70%, 95%, and 100% for 50 min,
and then embedded with Epon 812 (Shell Chemical,
London, UK) for polymerization. The embedded cells
were sectioned to achieve a thickness of 75 nm using a
Reichert ultramicrotome, and the samples were mounted
onto 200 mesh copper grids. After negative staining with
uranyl acetate and lead citrate for 5 min, the grids were vi-
sualized using an H600 transmission electron microscope
(Hitachi Ltd, Chiyoda-ku, Japan) with an operating voltage
of 60 kV.CT imaging of an atherosclerotic mice model
We used an apolipoprotein-E-gene-deficient (ApoE−/−)
mice model of atherosclerosis in the experiment [35]. This
animal model is generally accepted in the field. This model
can imitate pathological changes in atherosclerotic lesions
with high consistency when fed with a Western diet [35].
Animal experiments and animal care were carried out ac-
cording to protocols approved by the Institutional Commit-
tee for Animal Care and in accordance with the policy of
the National Ministry of Health. For CT imaging, ApoE−/−
mice (30 to 45 g, 1 year old, n = 8) purchased from the
Shanghai Research Center for Model Organisms (Shanghai,
China) were anesthetized by intraperitoneal injection of
pentobarbital sodium (40 mg/kg). PEGylated Au DENPs
(2.0 μmol Au/g body weight) dispersed in PBS buffer were
then intravenously injected into the mice through the tail
vein. The mice were scanned by a micro-CT imaging sys-
tem (eXplore Locus, GE Healthcare, London, Ontario,
Canada) with a tube voltage of 80 kV, an electrical current
of 450 μA, and a slice thickness of 45 μm. CT scanning was
performed both before and after intravenous injection of
PEGylated Au DENPs (100 μL, [Au] = 0.1 M) at time points
of 20 min, 2, 4, and 6 h post-injection, respectively. Images
were reconstructed on a micro-CT imaging workstation
using the following parameters: voxel, 45 × 45 × 45 μm;
display field of view, 10 to 25 mm. CT values were ac-
quired on the same workstation using the software sup-
plied by the manufacturer.Histological characteristics and macrophage uptake of
PEGylated Au DENPs
After micro-CT scanning, the animals were anesthetized
and perfusion-fixation was performed. The heart, lung,
liver, spleen, kidney, intestine, and vessel were harvested
and immediately fixed in a 4% formalin solution. Then
the organs were dehydrated and embedded with paraffin.
The paraffin-embedded samples were cut into 5-μm sec-
tions using a conventional microtome. For silver stain-
ing, the sections were dewaxed, washed thoroughly in
PBS, and stained with the silver enhancement kit ac-
cording to the manufacturer's instructions. Sections were
then washed with PBS and counterstained with 1% nu-
clear fast red. After washing thrice with PBS, the sec-
tions were then air-dried, dehydrated, and mounted onto
cover slips for light microscope observation.
For HE staining, the pre-treated sample sections were
dipped in a Coplin jar containing hematoxylin for 30 s.
The samples were then rinsed with water for 1 min and
stained with 1% eosin Y solution for 30 to 60 s. Finally,
the cover slips were dehydrated and mounted onto glass
slides before microscopic imaging.
In vivo biodistribution of PEGylated Au DENPs
After CT imaging of macrophages in ApoE−/− mice
model of atherosclerosis at 6 h post-injection of PEGy-
lated Au DENPs via intravenous injection, the mice were
euthanized. Then, the heart, lung, stomach, spleen, liver,
intestine, kidney, testicle, blood, and brain were ex-
tracted and weighed. The organs were cut into 1- to 2-
mm2 pieces and incubated in aqua regia solution for 4 h.
Au content was determined by a Leeman Prodigy in-
ductively coupled plasma-atomic emission spectroscopy
(ICP-AES) system (Teledyne Leeman Labs, Hudson,
NH, USA).
Statistical analysis
The data were expressed as mean values ± standard devi-
ation (SD). For quantitative comparison and analysis, the
values were evaluated by Student's t-test and a one-way
analysis of variance (ANOVA) method. A probability
value 0.05 was considered to indicate statistical signifi-
cance, and the data were labeled with (*) for p < 0.05 and
(**) for p < 0.01.
Results and discussion
Synthesis of PEGylated Au DENPs
Our previous work [29] has shown that G5.NH2 dendri-
mers modified with mPEG-MAL (G5.NH2-mPEG) can
be used as templates to entrap AuNPs with higher Au
loading content and good stability. The modification of
mPEG-MAL effectively improved the cytocompatibility
of the formed PEGylated Au DENPs.
Figure 1 UV-vis spectrum (a) and TEM image (b) of PEGylated Au DENPs.
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the experimental protocol reported in our previous report
[29]. The formed PEGylated Au DENPs were character-
ized using UV-vis spectrometry and TEM (Figure 1). In
Figure 1a, the PEGylated Au DENPs had a typical surface
plasmon resonance (SPR) peak at around 515 nm, indicat-
ing the presence of AuNPs. TEM image demonstratedFigure 2 Characterization of macrophages. Immunofluorescence stainin
macrophage markers F4/80 (red, a) and MAC-3 (red, b) and the nuclei were
F4/80 surface antigen was positive (98.6 ± 0.4) (c), whereas the isotype conthat the formed Au DENPs were relative uniform in
morphology with a mean diameter of 3.2 nm (Figure 1b),
in agreement with our previous report [29].
Characterization of macrophages
Ana-1 cells adopted a more uniform round-shaped popu-
lation (Figure 2a,b). Immunofluorescence staining showedg showed that more than 90% of the Ana-1 cells expressed the
stained with DAPI. Flow cytometry analysis of Ana-1 cells showed that
trol was negative (d). Scale bar measures 100 μm.
Figure 3 CCK-8 assay of the viability of macrophages treated
with PEGylated Au DENPs. CCK-8 assay of the viability of
macrophages treated with PEGylated Au DENPs with different
concentrations for 24 h (n = 4).
Figure 4 Transverse micro-CT images and CT values of the Ana-1 cell
Ana-1 cell suspensions incubated with PEGylated Au DENPs with different
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macrophage special markers of F4/80 (Figure 2a) and
MAC-3 (Figure 2b) and the cell nuclei were stained with
DAPI. Phenotypic analysis by flow cytometry showed that
the Ana-1 cells used in these experiments were strongly
positive for macrophage surface antigen F4/80 (98.6 ± 0.2)
(Figure 2c), whereas the isotype control was negative
(Figure 2d).
Cytotoxicity of PEGylated Au DENPs
Prior to using the PEGylated Au DENPs for molecular CT
imaging, the in vitro cytotoxicity of the NPs to macro-
phages should be evaluated. The cytotoxicity of PEGylated
Au DENPs was tested by CCK-8 assay of the viability of
Ana-1 cells treated with the particles (Figure 3). Macro-
phages incubated with PEGylated Au DENPs at the Au
concentration range of 100 to 300 μM had a similar cell
viability compared with the untreated control cells (p >
0.05, n = 4). Only at the Au concentration up to 400 μM,
the PEGylated Au DENPs started to display cytotoxicity.
The non-cytotoxicity of PEGylated Au DENPs at Aususpensions. Transverse micro-CT images (a) and CT values (b) of the
Au concentrations for 24 h (n = 3).
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modification is a powerful strategy to significantly enhance
the biocompatibility of Au DENPs for macrophage im-
aging applications.
Cell apoptosis is regarded as one of the most important
characteristics for cytotoxicity [36]. To test the influence
of PEGylated Au DENPs on macrophage apoptosis, the
cells incubated with the particles were analyzed by flow cy-
tometry (Additional file 1: Figure S1). The apoptotic index
of Ana-1 cells treated with PEGylated Au DENPs at Au
concentrations of 100 and 300 μM were estimated to be
3.3% ± 0.29% (Additional file 1: Figure S1b) and 3.57% ±
0.16% (Additional file 1: Figure S1c), respectively, with no
statistically significant difference from that of the control
cells treated with PBS (2.6% ± 0.27%, p > 0.05). This result
suggests that PEGylated Au DENPs have no apoptotic ef-
fect on macrophage. Thus, the combined results of CCK-8
assay for cell cytotoxicity and flow cytometry analysis for
cell apoptosis indicate that the PEGylated Au DENPs are
non-cytotoxic in the given concentration range, which is
essential for their uses in CT imaging of macrophages in
atherosclerosis.
In vitro micro-CT imaging
To prove that PEGylated Au DENPs enable CT imaging
of macrophages in vitro, Ana-1 cells incubated with PEGy-
lated Au DENPs with two different concentrations (100
and 300 μM) for 4 h were imaged (Figure 4a). Given the
fact that it is difficult to visually distinguish the brightness
of CT images of macrophages treated with Au DENPs,
quantitative analysis of the CT signal intensity is necessary.Figure 5 Representative images of Ana-1 cells subjected to silver stai
the cells incubated with PEGylated Au DENPs (at the Au concentration of 1
of cells incubated with PEGylated Au DENPs at the Au concentration of 30
square area in (d). The black arrow in (e) shows the domain of Au DENPs.Quantitative analysis of the CT values of macrophages
(Figure 4b) showed that the CT value of Ana-1 cells incu-
bated with PEGylated Au DENPs at the Au concentration
of 300 μM was significantly higher than that of the cells
incubated at a lower concentration (100 μM) (p < 0.05)
and that of the negative control cells (p < 0.01). The higher
CT values of macrophages at a higher concentration of
PEGylated Au DENPs (300 μM) may be associated with
the cellular uptake of more particles, which enable CT im-
aging of macrophages in vitro.
Cellular uptake of PEGylated Au DENPs
The uptake of PEGylated Au DENPs in the Ana-1 cells
was confirmed by silver staining. As shown in Figure 5,
accumulated black spots of silver staining were found in
the cytoplasm of Ana-1 cells treated with PEGylated Au
DENPs (at the Au concentration of 100 μM (b) and
300 μM (c)) for 24 h. The color of the spots became dar-
ker at a higher Au concentration, which implies the in-
crease in cellular uptake of PEGylated Au DENPs. In
contrast, the Ana-1 cells treated with PBS did not show
any black spots (Figure 5a).
TEM imaging of macrophages treated with PEGylated
Au DENPs was also performed to identify the particle dis-
tribution in subcellular structures. After incubation with
PEGylated Au DENPs (300 μM) for 24 h, numerous high
electron-staining particles were found in the cytoplasm of
cells (Figure 5d,e), especially in the lysosomes or phago-
cytic vacuoles. By sharp contrast, no electron-staining par-
ticles were observed in the cytoplasm of the control Ana-1
cells treated with PBS (Additional file 2: Figure S2). Thening and TEM. (a) Negative control cells treated with PBS buffer and
00 μM (b) and 300 μM (c) for 24 h). The image (d) shows TEM images
0 μM for 24 h; and the image (e) shows the magnified view of the
Scale bar measures 100 μm.
Figure 6 Representative in vivo micro-CT images of macrophages in ApoE−/− mice model of atherosclerosis. Representative in vivo micro-CT
images of macrophages in ApoE−/− mice model of atherosclerosis before and after intravenous injection with PEGylated Au DENPs (100 μL, [Au] = 0.1 M)
for 20 min, 2, 4, and 6 h. (a) Transverse planes, (b) coronal planes, (c) sagittal planes, and corresponding 3D renderings of in vivo CT images (d, e).
Figure 7 CT values (HU) of different organs before injection
and at different time points. CT values (HU) of different organs
before injection and at different time points post-intravenous
injection of PEGylated Au DENPs (100 μL, [Au] = 0.1 M). Abbreviation:
pulmonary vein (PA), inferior vena cava (IVC).
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cytized by macrophages instead of adhering to the surface
of cells. The internalization of PEGylated Au DENPs likely
occurs through two different mechanisms, such as phago-
cytosis and diffusion via cell walls, in agreement with pre-
vious literature reports [37,38]. The TEM data also verify
that the incubation of PEGylated Au DENPs with a high
Au concentration (300 μM) do not significantly affect the
morphology and subcellular structures of cells, corrobor-
ating the CCK-8 and cell apoptosis assay data.
CT imaging of an atherosclerotic mice model
We next used the PEGylated Au DENPs for CT imaging
of an atherosclerotic mice model. ApoE−/− mice were
intravenously injected with PBS solutions containing
PEGylated Au DENPs ([Au] = 0.1 M, 100 μL). The micro-
CT images of a mouse at a transverse section, coronal
plane, sagittal plane, and 3D reconstructed images are
shown in Figure 6. The pulmonary artery (PA) pointed by
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red arrow (Figure 6b,c), and abdominal aorta (AA) of the
mice pointed by a black arrow (Figure 6b,c) can be clearly
seen. In a coronal plane of the micro-CT images
(Figure 6b), the white arrow points to the renal vein, while
the red arrow points to the IVC. In the sagittal plane of
the micro-CT images (Figure 6c), the black arrow points
to the AA, and it is clear that the vessels show an appar-
ent enhancement after administration of PEGylated Au
DENPs with a CT value higher than that before injection.
Our results show that with the post-injection time, PEGy-
lated Au DENPs may be able to diffuse into the entire
macrophage area and are phagocytized by the macro-
phages. Thus, the vessels gradually became clearer andFigure 8 Representative HE staining and silver staining of main visce
staining of main visceral organs in ApoE−/− mice before (control) and aftermore defined. In addition, the liver regions of the mice were
also be easily discerned at 4 and 6 h post-administration of
PEGylated Au DENPs in the reconstructed 3D CT images
(Figure 6d,e). Our results suggest that modification of Au
DENPs with PEG molecules can prolong their blood cir-
culation time in the ApoE−/− mice by decreasing the rapid
uptake and clearance in the RES.
Careful analysis of the CT values of the macrophage area
at different time points shows that even at 6 h post-injection
of the PEGylated Au DENPs, the CT values of the macro-
phage areas are still significantly higher than those of the
macrophage areas before injection. In contrast to the CT
values of PA, heart, liver, and IVC, which all display a sig-
nificant increase after injection of PEGylated Au DENPs,ral organs in ApoE−/− mice. Representative HE staining and silver
intravenous injection with PEGylated Au DENPs for 6 h.
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slightly similar to those before the injection of the parti-
cles (Figure 7). Therefore, part of the PEGylated Au
DENPs could be transported to the macrophage sites and
be ingested by macrophages [39,40], enabling effective CT
imaging of blood pool in the atherosclerotic mice, which
is highly important for early stage diagnosis of atheroscler-
otic diseases.
In vivo macrophage uptake of PEGylated Au DENPs
To investigate the safety of PEGylated Au DENPs ([Au] =
0.1 M, 100 μL) in ApoE−/− mice and also the impact of the
particles on the tissue structures, the major organs of the
mice were extracted after 6 h post-injection of the PEGy-
lated Au DENPs. Then HE staining and silver staining of
the tissue sections from the extracted major organs were
performed and observed using optical microscopy. HE
staining (Figure 8) results reveal that the structure and
morphology of the major organ tissues do not have appar-
ent changes after intravenous injection of the PEGylated
Au DENPs when compared with the control groups before
injection. These results suggest that the PEGylated Au
DENPs ([Au] = 0.1 M, 100 μL) are safe and do not affect
the biological function of the organs. From silver staining
results, it can be seen that after about 6 h of metabolism,
Au DENPs (black spots) are able to be identified mainly in
the vessel, liver, and spleen regions, with significantly
smaller uptake in the lung, kidney, heart, and intestines.
Biodistribution of PEGylated Au DENPs
The macrophage uptake and biodistribution of PEGylated
Au DENPs were analyzed after 6 h post-intravenousFigure 9 Biodistribution of PEGylated Au DENPs in different organs. D
mice model.injection. ICP-AES was performed to quantify the Au con-
centration in the major organs such as heart, lung, stom-
ach, spleen, liver, intestine, kidney, testicle, blood, and
brain in the intravenous injection group with PEGylated
Au DENPs and the control group without PEGylated Au
DENP treatment (Figure 9). The results reveal that the
spleen has the most significant Au uptake. After 6 h post-
intravenous injection, the relatively high uptake of Au in
the blood suggests that the PEGylated Au DENPs are able
to escape from the RES located in the liver and pass
through the renal filter, thereby enhancing their circulation
time in the ApoE−/− mice. Detailed pharmacokinetic inves-
tigations of the PEGylated Au DENPs at extended time
points are necessary for a complete understanding of the
metabolism and biodistribution of the Au DENPs.
Conclusions
In summary, PEGylated Au DENPs were synthesized and
used as contrast agents for CT imaging of macrophages as-
sociated with atherosclerosis in vitro and in vivo. The com-
bined results of CCK-8 assay and flow cytometry analysis
show that the PEGylated Au DENPs are non-cytotoxic at
the Au concentration up to 300 μM. Silver staining and
TEM data confirm that the PEGylated Au DENPs can
be efficiently phagocytized and are mainly located in the ly-
sosomes of macrophages. Further in vitro CT imaging of
Ana-1 cells treated with the PEGylated Au DENPs and
in vivo blood pool CT imaging of ApoE−/− mice intraven-
ously injected with the particles indicates that the devel-
oped PEGylated Au DENPs are able to image macrophages
in vitro and the atherosclerotic mice in vivo. Findings from
our study suggest that the developed Au DENPs have aata were obtained by ICP-AES at 6 h post-injection in an ApoE−/−
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http://www.nanoscalereslett.com/content/9/1/529great potential to be used as contrast agents for CT im-
aging of blood pool in atherosclerotic mice, which is
important for the understanding of the pathological
physiology of cardiovascular disease.
Additional files
Additional file 1: Figure S1. Flow cytometry analysis of apoptosis of
macrophages treated without PEGylated Au DENPs (a) or with PEGylated
Au DENPs at Au concentration of 100 μM (b) and 300 μM (c) for 24 h
(n = 4).
Additional file 2: Figure S2. Representative TEM images of Ana-1 cells
without treatment with PEGylated Au DENPs (a). The image (b) shows
the magnified view of the square area in (a).
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